Hong Kong Stocks Movement | DUALITYBIO-B (09606) Rises Over 3% in Early Trading as DB-1310 Receives FDA Fast Track Designation

Stock News12-19 09:52

DUALITYBIO-B (09606) surged over 3% in early trading, reaching HK$318 with a turnover of HK$23.3955 million. The company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate, DB-1310.

The FTD is for treating adult patients with advanced/unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer (IHC 0, 1+, or 2+/ISH-negative) who have previously received endocrine therapy, CDK4/6 inhibitors, and may or may not have undergone chemotherapy in the unresectable or metastatic setting, or experienced disease recurrence within six months of completing adjuvant chemotherapy.

DB-1310 is the first HER3-ADC drug globally to receive FTD for this indication. The broad FTD scope covers both chemotherapy-naïve and chemotherapy-resistant scenarios in HR+/HER2- breast cancer, which is expected to accelerate its clinical development in frontline and later-line treatment settings.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment